Introduction {#sec1_1}
============

Iron overload is a consequence of iron accumulation that exceeds iron loss. Mechanisms that can lead to iron overload can be classified as absorption of excessive amounts of normal dietary iron (e.g., hemochromatosis and disorders of ineffective erythropoiesis) \[[@B1]\], absorption of excessive amounts of supplemental iron (medicinal iron overload) \[[@B2]\], and repeated erythrocyte transfusion (e.g., hemolytic anemia \[[@B3], [@B4]\], aplastic anemia, sideroblastic anemia, MDS, and acute leukemia \[[@B5]\]). In some disorders, more than one mechanism might contribute to the development of iron overload, e.g., iron overload in thalassemia patients can be due to ineffective erythropoiesis and repeated blood transfusions \[[@B6]\]. We describe a patient who developed iron overload with a background of anemia secondary to end stage renal disease (ESRD), for which she received multiple intravenous iron doses.

Case Presentation {#sec1_2}
=================

A 56-year-old female with a history of kidney transplantation at 2 times (first 2002, second 2017), referred to the hematology clinic due to persistently elevated ferritin level with the impression of iron overload (iatrogenic).

She has multiple medical problems for which she is being treated or was treated in the past, which includes a history of breast cancer that was treated surgically and with chemotherapy (and tamoxifen), diabetes mellitus, hypertension, and herpes zoster infection that was complicated by post-herpetic neuralgia.

Clinically the patient did not complain of symptoms that can be attributed to organ dysfunction that is related to iron overload. Her laboratory workup showed: ferritin: 1,219.0 μg/L (persistently above 500 μg/L for 4 years), serum iron: 14 μmol/L, TIBC: 50 μmol/L, iron saturation: 28%, ALT: 11.7 U/L, AST: 12 U/L, alkaline phosphatase: 78.0 U/L, total bilirubin: 4.0 μmol/L, serum albumin: 35.5 g/L, INR: 1.0. The patient was offered MRI of the liver to measure liver iron concentration (LIC); however, she refused to get it performed.

Discussion {#sec1_3}
==========

Iron overload used to be considered rare in hemodialysis patients, especially currently where erythropoiesis-stimulating agents are regularly used to manage anemia in hemodialysis patients \[[@B6]\]. However, treatment with these agents can lead to functional iron deficiency, which necessitates iron supplementation \[[@B7]\].

Excessive iron infusions can lead to increased mortality and cardiovascular events in hemodialysis patients, these effects of iron supplementation can be attributed to the increased oxidative stress and induction of mononuclear cell adhesion to endothelial cells, which is an important step in the pathogenesis of atherosclerosis \[[@B8]\]. The risks of cerebrovascular and cardiovascular disease, infection, and hospitalization were significantly higher among patients who were treated with high weekly doses of intravenous iron compared with no intravenous iron \[[@B9]\].

The liver is the main iron storage site and the LIC gives a very accurate picture of total body iron stores in patients with secondary hemosiderosis such as thalassemia major \[[@B2]\].

Excess iron may be deposited in the liver, heart, and endocrine organs, which can lead to liver cirrhosis, heart failure, and several endocrinopathies \[[@B10], [@B11], [@B12], [@B13], [@B14]\].

As with other etiologies of liver cirrhosis (e.g., alcoholic liver disease, viral hepatitis, and NASH) development of liver cirrhosis due to iron deposition takes many years, and with the observed short life span of ESRD patients, it may account for scarcity of iron overload-induced cirrhosis in this population. Keeping this in mind, increased LIC in dialysis patients can be utilized to predict and assess patients with possible iron overload rather than the development of liver cirrhosis or other clinical consequences of iron overload \[[@B15]\].

Among transfusion-dependent thalassemia major patients, it is observed that they have a higher incidence of primary hypothyroidism with a frequency that varies between different reports, and it ranges from 4 to 29%, based on the level of FT4/T4 and TSH. A lower prevalence of hypothyroidism is found among patients with lower iron load, as measured by ferritin levels \[[@B16]\].

A study that investigated endocrinopathies in patients with β-thalassemia intermedia grouped the patients as non-transfused versus infrequently transfused patients.

The mainstay of iron overload treatment is phlebotomy in non-anemic patients and iron chelation therapy in anemic patients. The challenge in hemodialysis patients with iron overload is that they are anemic and the use of iron with the available iron chelators is generally contraindicated in ESRD/hemodialysis patients. Currently there are three commercially available iron chelators, deferoxamine, deferiprone, and deferasirox \[[@B17]\].

Conclusion {#sec1_4}
==========

Intravenous iron in patients with end stage renal failure should be used judiciously and should be monitored by serum ferritin and preferably LIC by MRI to avoid iatrogenic iron overload.
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